ArticleLa Radiologia medica2018
Effects of serial macrocyclic-based contrast materials gadoterate meglumine and gadobutrol administrations on gadolinium-related dentate nuclei signal increases in unenhanced T1-weighted brain: a retrospective study in 158 multiple sclerosis (MS) patients.
Article in La Radiologia medica, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 65 citations in OpenAlex.
- EPR-based Assessment of Gadolinium-based Contrast Agent Retention and Gadolinium Transchelation in Inflamed Murine Brain.Investigative radiology · 2026Article
- Gadolinium toxicity: mechanisms, clinical manifestations, and nanoparticle role.Archives of toxicology · 2025Review
- Toxicity Mechanisms of Gadolinium and Gadolinium-Based Contrast Agents-A Review.International journal of molecular sciences · 2024Review
- Gadolinium-based contrast agent exposures and physical and cognitive disability in multiple sclerosis.Journal of neuroimaging : official journal of the American Society of Neuroimaging · 2023Observational
- The benefits and side effects of gadolinium-based contrast agents in multiple sclerosis patients.Revista da Associacao Medica Brasileira (1992) · 2022Article
- Gadolinium: pharmacokinetics and toxicity in humans and laboratory animals following contrast agent administration.Archives of toxicology · 2022Review
- Evaluation of the effect of multiple administrations of gadopentetate dimeglumine or gadoterate meglumine on brain T1-weighted hyperintensity in pediatric patients.Pediatric radiology · 2021Article
- Narrative review of multiparametric ultrasound in parotid gland evaluation.Gland surgery · 2020Review
- Pituitary magnetic resonance imagingGland surgery · 2020Review
- Apparent diffusion coefficient magnetic resonance imaging (ADC-MRI) in the axillary breast cancer lymph node metastasis detection: a narrative review.Gland surgery · 2020Review
- Undetectable gadolinium brain retention in individuals with an age-dependent blood-brain barrier breakdown in the hippocampus and mild cognitive impairment.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2019Article
- Visible T1-hyperintensity of the dentate nucleus after multiple administrations of macrocyclic gadolinium-based contrast agents: yes or no?Insights into imaging · 2019Article
- High-resolution magnetic resonance imaging at 3T of pituitary gland: advantages and pitfalls.Gland surgery · 2019Review
- Cumulative gadodiamide administration leads to brain gadolinium deposition in early MS.Neurology · 2019Article
- Gadolinium Retention in the Brain: An MRI Relaxometry Study of Linear and Macrocyclic Gadolinium-Based Contrast Agents in Multiple Sclerosis.AJNR. American journal of neuroradiology · 2019Article
- Standardized assessment of the signal intensity increase on unenhanced T1-weighted images in the brain: the European Gadolinium Retention Evaluation Consortium (GREC) Task Force position statement.European radiology · 2019Review
- Diagnostic performance of an unenhanced MRI exam for tumor follow-up of the optic pathway gliomas in children.Neuroradiology · 2019Article
- Diagnostic value/performance of radiological liver imaging during chemoterapy for gastrointestinal malignancy: a critical review.Acta bio-medica : Atenei Parmensis · 2019Review
- Advances in diagnostic and interventional radiology.Acta bio-medica : Atenei Parmensis · 2019Article
- Relationship between diagnostic imaging features and prognostic outcomes in gastrointestinal stromal tumors (GIST).Acta bio-medica : Atenei Parmensis · 2019Review
Corrections and comments
- Commented on by
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo perform T1 signal intensity (SI) measurements in the dentate nuclei of adult patients with confirmed multiple sclerosis (MS) after serial administrations of the macrocyclic gadolinium-based contrast agents (GBCAs), gadoterate meglumine and gadobutrol. MATERIALS AND
methodsThis retrospective study was approved by the institutional review board and informed consent was waived. A review of our PACS database for the period from March 1, 2007 to July 31, 2016 revealed 158 confirmed MS patients who received exclusively either gadoterate meglumine (n = 81) or gadobutrol (n = 77) for diagnosis and follow-up. SI measurements on unenhanced T1-weighted images were performed on all scans of all patients and at regions of interest (ROIs) positioned on the dentate nucleus (DN) and pons. The dentate nucleus-to-pons (DNP) T1-SI ratio was subsequently calculated. Unpaired T test and regression analysis were used to evaluate statistical differences.
resultsAn increase in DNP was noted between the first and last MR examinations for both gadoterate meglumine (0.0032 ± 0.0216) and gadobutrol (0.0019 ± 0.0346). Although the differences were not statistically significant based across the entire patient population, visible T1 hyperintensity in the DN was noted in approximately one-third of all patients in each group that received at least five administrations of either GBCA.
conclusionsSI increases on unenhanced T1-weighted images possibly indicative of gadolinium retention occur after serial administrations of the macrocyclic GBCAs, gadoterate meglumine and gadobutrol.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.